+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Class III Beta-tubulin Expression in Non-small Cell Lung Cancer: A Predictive Factor for Paclitaxel Response



Class III Beta-tubulin Expression in Non-small Cell Lung Cancer: A Predictive Factor for Paclitaxel Response



Anticancer Research 35(5): 2669-2674



In order to clarify whether class III beta-tubulin (TUBB3) is a predictive marker for paclitaxel (PTX) chemotherapy, chemosensitivity was examined using an in vitro drug sensitivity assay. Twelve specimens from non-small cell lung cancer (NSCLC) patients were obtained for dose-response curve analysis and measurement of the half-maximal effective dose (ED50) of PTX using the histoculture drug response assay (HDRA). Forty-one specimens were evaluated using the HDRA and the inhibition ratio (IR) at a concentration of 25 μg/ml PTX (IR25) was measured. TUBB3 expression was evaluated by H-score in immunohistochemical staining. The ED50 of PTX was 24.5 ± 8.06 μg/ml. The median H-score was significantly higher (p=0.0076) in the high effective dose (HE)-group (ED50 >25 μg/ml) than in the low effective (LE)-group (ED50 ≤ 25 μg/ml). The mean IR25 was 53.8 ± 26.6%. The median H-score for the high-inhibition ratio (HI)-group (IR25 >50%) was significantly higher (p=0.0337) than the low-inhibition ratio (LI)-group (IR25 ≤ 50%). High TUBB3 expression in NSCLC appeared to correlate with lower PTX sensitivity.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 057411561

Download citation: RISBibTeXText

PMID: 25964544


Related references

Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Molecular Cancer Therapeutics 4(12): 2001-2007, 2005

Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer 64(3): 326-333, 2008

Association between class III β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis. Lung Cancer 77(1): 9-15, 2012

Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clinical Cancer Research 11(15): 5481-5486, 2005

Is class III beta-tubulin a true predictive marker of sensitivity to vinorelbine in non-small cell lung cancer? Chemosensitivity data evidence. Anticancer Research 31(3): 999-1005, 2011

Expression of ERCC1 and class IIIbeta tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer. Pathology International 59(12): 863-867, 2010

Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bulletin du Cancer 92(2): E25-E30, 2005

Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials. Annals of Oncology 23(1): 86-93, 2012

Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer. Journal of Thoracic Oncology 5(3): 320-325, 2010

High expression levels of class III β-tubulin in resected non-small cell lung cancer patients are predictive of improved patient survival after vinorelbine-based adjuvant chemotherapy. Oncology Letters 6(1): 220-226, 2013

The relationship between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase, excision repair cross-complementation group 1 and class III β-tubulin, and the therapeutic effect of S-1 or carboplatin plus paclitaxel in non-small-cell lung cancer. Molecular and Clinical Oncology 9(1): 21-29, 2018

Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clinical Cancer Research 13(3): 994-999, 2007

Class III beta-tubulin expression in tumor cells is correlated with resistance to docetaxel in patients with completely resected non-small-cell lung cancer. Internal Medicine 48(4): 203-208, 2009

Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. Journal of Clinical Oncology 17(6): 1786-1793, 1999

Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation. Cancer ChemoTherapy and Pharmacology 64(3): 565-573, 2009